{"entity":{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","aka":["Neonc Technologies, Inc."],"tldr":"Neonc Technologies is a United States-based biotechnology company running 3 late-stage cancer trials of NEO212 Oral and NEO100 in glioma & glioblastoma, cervical cancer and colorectal cancer.","summary":"Neonc Technologies, based in Calabasas, the United States, is a biotechnology company listed as NASDAQ: NTHI. NeOnc develops drug delivery therapeutics for central nervous system diseases, using a perillyl-alcohol-based platform intended to transport therapeutics across the blood-brain barrier. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing NEO212 Oral and NEO100 in glioma & glioblastoma, cervical cancer, colorectal cancer, oesophageal cancer and gastric & gastro-oesophageal junction cancer. The largest, NCT06047379 (Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis), plans to enrol 134 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.neonc.com"},{"label":"ClinicalTrials.gov: trials led by Neonc Technologies","url":"https://clinicaltrials.gov/search?lead=Neonc%20Technologies%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma","cervical","colorectal","esophageal","gastric","head-and-neck","melanoma","merkel-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06047379","nct02704858"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Calabasas","country":"US","companyType":"biotech","website":"https://www.neonc.com","ticker":"NASDAQ: NTHI","stage":"public","investors":[],"funding":[]},"route":"/companies/neonc-technologies/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"trial":[{"id":"nct06047379","kind":"trial","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","route":"/trials/nct06047379/"},{"id":"nct02704858","kind":"trial","name":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","route":"/trials/nct02704858/"}]}}